Deploying smart weapons in the fight against cancer.
Bellicum Pharmaceuticals, Inc. is developing novel therapies that can be precisely controlled after delivery, for enhanced efficacy and ultimate safety. BPX-101 is an autologous vaccine in clinical development for patients with prostate cancer, and CaspaCIDe™ DLI is in clinical development for patients undergoing hematopoietic stem cell transplantation.
Bellicum: Latin, (noun) Military signal to mobilize an attack; call to war
Now Hiring! Bellicum is now hiring. Please see our careers page for more information.
Careers
|
||
Newsroom
- November 2, 2011 - Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients
- March 25, 2011 - Bellicum Pharmaceuticals Awarded $5.7 Million by the Cancer Prevention and Research Institute of Texas
- March 8, 2011 - Journal of Clinical Investigation Publishes Data Demonstrating Enhanced Antitumor Efficacy of Second Generation DeCIDe™ Technology